1. Home
  2. KROS

KROS

Keros Therapeutics Inc.

Logo Keros Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Founded: 2015 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 2.1B IPO Year: 2020
Target Price: $86.00 AVG Volume (30 days): 375.6K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.20 EPS Growth: N/A
52 Week Low/High: $27.02 - $73.00 Next Earning Date: 05-02-2024
Revenue: $151,000 Revenue Growth: N/A
Revenue Growth (this year): 4155.63% Revenue Growth (next year): -99.65%

Share on Social Networks: